Interventions. Copies: This document is available on the World Wide Web sites of the
American College of Cardiology (www. cardiosource. org), the American Heart Association …

Patients undergoing early surgery after coronary stent implantation are at increased risk for
mortality from ischemic and hemorrhagic complications. The optimal antiplatelet strategy in …

This article discusses platelet active drugs as part of the Seventh American College of Chest
Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based …

This article about currently available antiplatelet drugs is part of the Antithrombotic and
Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical …

Rationale: The hallmark of severe influenza virus infection is excessive inflammation of the
lungs. Platelets are activated during influenza, but their role in influenza virus pathogenesis …

Background—Eptifibatide reduces major adverse cardiac events in patients with acute
coronary syndromes undergoing percutaneous coronary intervention (PCI). Intracoronary …

Background Monocyte–platelet aggregates (MPAs) represent the crossroads between
thrombosis and inflammation, and targeting this axis may suppress thromboinflammation …

Glycoprotein (GP) IIb‐IIIa antagonists inhibit the aggregation of activated platelets. Three
agents are approved for clinical use. In this review, the characteristics of each agent, their …

Abstract Platelet GPIIb/IIIa antagonists are not only used to prevent platelet aggregation, but
also in combination with thrombolytic agents for the treatment of coronary thrombi. Recent …

Background—The relative anti-aggregatory effects of currently prescribed platelet
glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary …